NCT03677336 - Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

August 24, 2020

Study Completion Date

August 24, 2020

Conditions

Infertility, FemaleInfertilityGenital Diseases, MaleGenital Diseases, FemaleProgesteroneDydrogesteroneHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of DrugsProgestins

Interventions

DRUG

Dydrogesterone Oral Tablet

Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days

DRUG

Micronized progesterone

Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days

DRUG

Placebo Dydrogesterone oral tablet

Tablet, indistinguishable from dydrogesterone oral tablet

DRUG

Placebo Micronized progesterone

Capsule, indistinguishable from micronized vaginal progesterone capsules

Trial Locations (1)

1090

Centrum voor Reproductieve Geneeskunde, Jette